Academic

ThromboGenics has a wide range of agreements with numerous academic institutes that have significant research expertise in the vascular area, and from which the Company has in-licensed a number of the therapeutic programmes that it currently has under development. These academic institutes include:

Prof. Dr. Marc Jacquemin

KULeuven, Belgium

• Center For Molecular and Vascular Biology, KULeuven
  The Company has two collaborations on projects that are in-licensed from this academic center, the development of microplasmin, staphylokinase, Anti-Factor VIII and Anti-VPAC.

Prof. Dr. Peter Carmeliet

Flanders Institute for Biotechnology (VIB)

The Company has an ongoing collaboration with the Center for Transgene Technology and Gene Therapy, a department of the VIB, on the pre-clinical characterisation of two of its programmes that were in-licensed from this institute, Anti-PlGF and PlGF.

Prof. Dr. Peter Verhamme

Scientific Advisory Boards

In addition to the above collaborations, ThromboGenics has Advisory Boards for several of its advanced programmes (namely, the Microplasmin-Vitreoretinal Advisory Board, the Microplasmin-Stroke Advisory Board, the Anti-Factor VIII Advisory Board, and the Anti-PlGF Advisory Board).